Join Our Team
Working with Amicus provides numerous opportunities to be inventive and purposeful, and where bold thinking and collaboration are highly valued—and expected.
We are currently seeking passionate and qualified candidates in various departments at our global locations.
At Amicus we are business led and science driven to deliver meaningful benefits to patients. We believe that our advanced product pipeline and platform technologies uniquely position us at the forefront of developing therapies to potentially address significant unmet needs for devastating rare and orphan diseases.
VIEW FULL PIPELINE →
Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders.
Migalastat, is a small molecule pharmacological chaperone for the treatment of Fabry disease that has been approved for use in the European Union (EU) under the brand name Galafold™ (migalastat) for adult and adolescent patients over the age of 16 with Fabry disease with an amenable mutation. MORE →
We are leveraging our biologics and Chaperone-Advanced Replacement Therapy (CHARTTM) to develop ATB200/AT2221, a novel treatment paradigm that consists of a uniquely engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure (designated ATB200), administered with a small molecule pharmacological chaperone (designated AT2221). MORE →
We are currently researching a potential first-in-class protein replacement therapy approach for CDKL5 deficiency in preclinical studies. CDKL5 (cyclin-dependent kinase-like 5) is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal braini development. MORE →
Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights.
We are a global biotechnology company at the forefront of advancing therapies for a range of rare and devastating diseases and our excellent team has a very big and a very bold vision.
Each program that we invest in has to have three key characteristics. It has to be in the rare diseases for a devastating disorder, the technology has to have the potential to be first in class or best in class, and the clinical data must be able to provide meaningful benefit for patients.
John F. Crowley
Chairman and Chief Executive Officer Amicus Therapeutics Inc.
MEET THE FULL LEADERSHIP TEAM →